PharPoint Research, Inc. Market Research Report

Background

Overview

PharPoint Research, Inc. is a privately held contract research organization (CRO) based in Durham, North Carolina. Established in 2007 by three industry veterans, the company specializes in providing comprehensive clinical trial services, including clinical operations, project management, biostatistics, and clinical data management. PharPoint serves a diverse clientele, ranging from small biotech firms to large pharmaceutical companies, across various therapeutic areas and clinical trial phases.

Mission and Vision

PharPoint's mission is to offer an alternative to traditional, rigid, and quality-compromised CROs by delivering flexible, client-focused solutions that prioritize both sponsor and patient needs. The company's vision is to be a trusted partner in drug development, fostering innovation and efficiency in clinical trials.

Industry Significance

Since its inception, PharPoint has supported over 1,000 clinical trials, maintaining a strong client retention rate of approximately 92%. The company's commitment to quality and client satisfaction has been recognized by industry awards, including the Triangle Business Journal's "Best Places to Work" in 2023 and 2024, and the "Most Innovative CRO" award in 2020.

Key Strategic Focus

Core Objectives

PharPoint aims to provide agile and scalable clinical trial solutions that meet the evolving needs of its clients, ensuring high-quality deliverables within industry-best timelines. The company emphasizes a collaborative approach, working closely with clients to achieve study goals efficiently.

Areas of Specialization

PharPoint specializes in various therapeutic areas, including infectious diseases, oncology, cardiovascular, central nervous system (CNS) disorders, and rare diseases. The company offers services across all clinical trial phases, from pre-IND to Phase IV.

Key Technologies Utilized

PharPoint employs advanced technologies such as electronic data capture (EDC) systems, clinical trial management systems (CTMS), and interactive voice response systems (IVRS) to enhance data collection, monitoring, and management processes. The company also partners with leading virtual trial technology providers to offer decentralized study solutions.

Primary Markets Targeted

PharPoint primarily targets the pharmaceutical, biotechnology, and medical device industries, offering tailored solutions to meet the specific needs of sponsors in these sectors. The company has expanded its global reach, including strengthening its European capabilities to access emerging markets.

Financials and Funding

Funding History

As a privately held company, PharPoint has not publicly disclosed detailed funding history or total funds raised. The company has experienced steady growth, as evidenced by its recognition in the Triangle Business Journal's "Fast 50" awards in multiple years, including 2011, 2012, and 2016.

Recent Funding Rounds

Specific details regarding recent funding rounds are not publicly available.

Notable Investors

Information about individual investors or venture capital firms involved with PharPoint is not publicly disclosed.

Utilization of Capital

While specific utilization details are not available, PharPoint has expanded its facilities, including the Wilmington, NC office, to accommodate growth and enhance service delivery.

Pipeline Development

Key Pipeline Candidates

PharPoint's pipeline development focuses on providing comprehensive clinical trial services across various therapeutic areas, including infectious diseases, oncology, cardiovascular, CNS disorders, and rare diseases. The company has participated in over 830 studies in infectious diseases alone, covering indications such as Hepatitis-C, HIV, Influenza, Hepatitis-B, and Ebola.

Stages of Clinical Trials

PharPoint offers services across all clinical trial phases, from pre-IND to Phase IV, ensuring comprehensive support throughout the drug development process.

Target Conditions

The company has experience in a wide range of conditions, with a notable focus on infectious diseases, oncology, cardiovascular, CNS disorders, and rare diseases.

Anticipated Milestones

Specific timelines for anticipated milestones are not publicly disclosed.

Technological Platform and Innovation

Proprietary Technologies

PharPoint utilizes proprietary technologies such as EDC systems, CTMS, and IVRS to streamline clinical trial processes and enhance data accuracy. The company also integrates virtual trial technologies to support decentralized study models.

Significant Scientific Methods

PharPoint employs advanced statistical methodologies and biostatistical analyses to support clinical trials, ensuring robust data interpretation and regulatory compliance.

Leadership Team

Executive Profiles

• Art Holmes, President and CEO: With over 32 years in the pharmaceutical industry, Mr. Holmes founded Databasics Consulting, Inc. and has held management positions at Quintiles Transnational Corp. and PharmaResearch Inc.

• Audra McRae, Chief Operating Officer: Ms. McRae has 30 years of experience in clinical research, including roles at North Carolina State University and Roche Biomedical. She has been integral in the development and success of two start-up CROs.

• Jennifer A. Elder, PhD, Chief Scientific Officer: Dr. Elder has 30 years of experience in statistical analyses for clinical trials, serving as the lead statistician on pivotal studies for novel antiretroviral medications.

• Jayme Swinson, MS, Vice President, Operations: Ms. Swinson leads operations with a focus on efficient clinical trial execution and client satisfaction.

• Moya Hawkins, Executive Director, Client Experience: Ms. Hawkins ensures exceptional client service and fosters strong sponsor relationships.

• Tracy Pflaumer, MS, Executive Director, Biostatistics and Statistical Programming Auxiliary Services: Ms. Pflaumer oversees biostatistical services, ensuring data integrity and regulatory compliance.

• Paul Johnson, Executive Director, Strategy Development: Mr. Johnson drives strategic initiatives to expand PharPoint's market presence and service offerings.

• Sean McRae, Executive Director, IT: Mr. McRae manages IT infrastructure, supporting clinical trial technologies and data security.

• Ryan Hager, Senior Director, Statistical Programming: Mr. Hager leads statistical programming efforts, ensuring accurate data analysis and reporting.

• Wendy Moffett, Director, Data Management and Database Programming: Ms. Moffett oversees data management processes, ensuring data quality and compliance.

• Stephanie Olsen, Director, Statistical Programming: Ms. Olsen manages statistical programming teams, delivering timely and accurate data analyses.

• Baker Sharpe, Director, Data Management and Database Programming: Mr. Sharpe ensures efficient data management and database programming to support clinical trials.

• Maribeth Owings, Director, Clinical Operations: Ms. Owings leads clinical operations, focusing on study execution and operational excellence.

• Ted Beverly, Director, IT: Mr. Beverly supports IT systems, enhancing technological capabilities for clinical trials.

• Nate Veney, Director, Human Resources: Mr. Veney manages HR functions, fostering a positive and productive work environment.

• Eleanor Haymond, Director, Finance: Ms. Haymond oversees financial operations, ensuring fiscal responsibility and strategic growth.

• Melisa Williamson, Director, Quality Assurance: Ms. Williamson ensures quality assurance processes, maintaining high standards in clinical trials.

Competitor Profile

Market Insights and Dynamics

The CRO industry is characterized by rapid growth,